Figure 3. Mutations detected by targeted sequencing of ctDNA prior to therapy initiation (Baseline), upon treatment (Treatment) and at disease progression (Progress).

Black dots at the respective time-point mark mutations that differ from the initial mutational profile generated at baseline prior to initiation of the respective therapy line.